These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 27287046)

  • 1. Multiscale Modeling of Antibody-Drug Conjugates: Connecting Tissue and Cellular Distribution to Whole Animal Pharmacokinetics and Potential Implications for Efficacy.
    Cilliers C; Guo H; Liao J; Christodolu N; Thurber GM
    AAPS J; 2016 Sep; 18(5):1117-1130. PubMed ID: 27287046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A mechanistic pharmacokinetic model elucidating the disposition of trastuzumab emtansine (T-DM1), an antibody-drug conjugate (ADC) for treatment of metastatic breast cancer.
    Bender B; Leipold DD; Xu K; Shen BQ; Tibbitts J; Friberg LE
    AAPS J; 2014 Sep; 16(5):994-1008. PubMed ID: 24917179
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modeling the efficacy of trastuzumab-DM1, an antibody drug conjugate, in mice.
    Jumbe NL; Xin Y; Leipold DD; Crocker L; Dugger D; Mai E; Sliwkowski MX; Fielder PJ; Tibbitts J
    J Pharmacokinet Pharmacodyn; 2010 Jun; 37(3):221-42. PubMed ID: 20424896
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved Tumor Penetration and Single-Cell Targeting of Antibody-Drug Conjugates Increases Anticancer Efficacy and Host Survival.
    Cilliers C; Menezes B; Nessler I; Linderman J; Thurber GM
    Cancer Res; 2018 Feb; 78(3):758-768. PubMed ID: 29217763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical implications of pathophysiological and demographic covariates on the population pharmacokinetics of trastuzumab emtansine, a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer.
    Gupta M; Lorusso PM; Wang B; Yi JH; Burris HA; Beeram M; Modi S; Chu YW; Agresta S; Klencke B; Joshi A; Girish S
    J Clin Pharmacol; 2012 May; 52(5):691-703. PubMed ID: 21953571
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of Drug-Antibody Ratio on Pharmacokinetics, Biodistribution, Efficacy, and Tolerability of Antibody-Maytansinoid Conjugates.
    Sun X; Ponte JF; Yoder NC; Laleau R; Coccia J; Lanieri L; Qiu Q; Wu R; Hong E; Bogalhas M; Wang L; Dong L; Setiady Y; Maloney EK; Ab O; Zhang X; Pinkas J; Keating TA; Chari R; Erickson HK; Lambert JM
    Bioconjug Chem; 2017 May; 28(5):1371-1381. PubMed ID: 28388844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a Translational Physiologically Based Pharmacokinetic Model for Antibody-Drug Conjugates: a Case Study with T-DM1.
    Khot A; Tibbitts J; Rock D; Shah DK
    AAPS J; 2017 Nov; 19(6):1715-1734. PubMed ID: 28808917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. On translation of antibody drug conjugates efficacy from mouse experimental tumors to the clinic: a PK/PD approach.
    Haddish-Berhane N; Shah DK; Ma D; Leal M; Gerber HP; Sapra P; Barton HA; Betts AM
    J Pharmacokinet Pharmacodyn; 2013 Oct; 40(5):557-71. PubMed ID: 23933716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Native mass spectrometry and ion mobility characterization of trastuzumab emtansine, a lysine-linked antibody drug conjugate.
    Marcoux J; Champion T; Colas O; Wagner-Rousset E; Corvaïa N; Van Dorsselaer A; Beck A; Cianférani S
    Protein Sci; 2015 Aug; 24(8):1210-23. PubMed ID: 25694334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evolution of Antibody-Drug Conjugate Tumor Disposition Model to Predict Preclinical Tumor Pharmacokinetics of Trastuzumab-Emtansine (T-DM1).
    Singh AP; Maass KF; Betts AM; Wittrup KD; Kulkarni C; King LE; Khot A; Shah DK
    AAPS J; 2016 Jul; 18(4):861-75. PubMed ID: 27029797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ado-trastuzumab emtansine: a HER2-positive targeted antibody-drug conjugate.
    Corrigan PA; Cicci TA; Auten JJ; Lowe DK
    Ann Pharmacother; 2014 Nov; 48(11):1484-93. PubMed ID: 25082874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An Agent-Based Systems Pharmacology Model of the Antibody-Drug Conjugate Kadcyla to Predict Efficacy of Different Dosing Regimens.
    Menezes B; Cilliers C; Wessler T; Thurber GM; Linderman JJ
    AAPS J; 2020 Jan; 22(2):29. PubMed ID: 31942650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms of enhanced drug delivery in brain metastases with focused ultrasound-induced blood-tumor barrier disruption.
    Arvanitis CD; Askoxylakis V; Guo Y; Datta M; Kloepper J; Ferraro GB; Bernabeu MO; Fukumura D; McDannold N; Jain RK
    Proc Natl Acad Sci U S A; 2018 Sep; 115(37):E8717-E8726. PubMed ID: 30150398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Statistical modeling of the drug load distribution on trastuzumab emtansine (Kadcyla), a lysine-linked antibody drug conjugate.
    Kim MT; Chen Y; Marhoul J; Jacobson F
    Bioconjug Chem; 2014 Jul; 25(7):1223-32. PubMed ID: 24873191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ADME of antibody-maytansinoid conjugates.
    Erickson HK; Lambert JM
    AAPS J; 2012 Dec; 14(4):799-805. PubMed ID: 22875610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanistic pharmacokinetic/pharmacodynamic modeling of in vivo tumor uptake, catabolism, and tumor response of trastuzumab maytansinoid conjugates.
    Wada R; Erickson HK; Lewis Phillips GD; Provenzano CA; Leipold DD; Mai E; Johnson H; Tibbitts J
    Cancer Chemother Pharmacol; 2014 Nov; 74(5):969-80. PubMed ID: 25186956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sortase Enzyme-Mediated Generation of Site-Specifically Conjugated Antibody Drug Conjugates with High In Vitro and In Vivo Potency.
    Beerli RR; Hell T; Merkel AS; Grawunder U
    PLoS One; 2015; 10(7):e0131177. PubMed ID: 26132162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ado-trastuzumab emtansine for the treatment of human epidermal growth factor receptor 2-positive metastatic breast cancer.
    Patel KC; Hageman K; Cooper MR
    Am J Health Syst Pharm; 2014 Apr; 71(7):537-48. PubMed ID: 24644113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody-Drug Conjugates: Pharmacokinetic/Pharmacodynamic Modeling, Preclinical Characterization, Clinical Studies, and Lessons Learned.
    Hedrich WD; Fandy TE; Ashour HM; Wang H; Hassan HE
    Clin Pharmacokinet; 2018 Jun; 57(6):687-703. PubMed ID: 29188435
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Positron-Emission Tomography of HER2-Positive Breast Cancer Xenografts in Mice with
    Al-Saden N; Lam K; Chan C; Reilly RM
    Mol Pharm; 2018 Aug; 15(8):3383-3393. PubMed ID: 29957952
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.